Navigation Links
Miriam Hospital receives renewal of NIH grant for AIDS Clinical Trials Group
Date:3/19/2014

(PROVIDENCE, R.I.) A $2.4 million grant renewal will support The Miriam Hospital's continued efforts in research and new treatments for HIV and AIDS. The Miriam Hospital is the largest HIV/AIDS care provider in the state.

The ACTG is a global network of 60 research sites with its operations and laboratory center based at Brigham and Women's Hospital in Boston. The ACTG conducts clinical trials in HIV-infected adults to test novel therapeutic interventions focused on HIV-associated inflammation and resulting end-organ disease, tuberculosis, viral hepatitis and HIV cure.

Karen Tashima, M.D., the lead researcher at The Miriam, received the National Institutes of Health grant renewal. Tashima leads the ACTG's Providence site, which operates under the program's Harvard/Boston/Providence Clinical Trials Unit. She says, "We are thrilled with the results that have come from the ACTG Network. The Miriam Hospital has been part of the Network since 2000. Our work has allowed us to foster new investigations and treatments for treating HIV and AIDS."

Tashima says, "The ACTG is an important HIV clinical studies network that, for example, proved that mother to child transmission could be dramatically reduced by having the pregnant woman take the anti-HIV medication AZT. Results of other ACTG studies have changed how we treat HIV infection, and have resulted in Department of Health and Human Services HIV guideline changes leading to improvements nationally in the standard of care for HIV treatment."

Dr. Tashima was the lead investigator and study chair for the OPTIONS trial that was conducted at 64 sites across the continental U.S. and in Puerto Rico. The OPTIONS trial was a multi-site study that showed patients with drug-resistant HIV can safely achieve viral suppression the primary goal of HIV therapy without incorporating the traditional class of HIV medications into their treatment regimen. The ACTG trial showed for the first time that treatment-experienced patients can leave out this class of medication, known as nucleoside reverse transcriptase inhibitors (NRTI), as part of the regimen. Treatment-experienced patients already need to take three active medications in order to achieve viral suppression, so eliminating NRTI medications can lessen pill burden and side effects.

The Miriam Hospital is the largest care provider in Rhode Island, treating more than 1,500 patients with HIV who are under ongoing care. These patients have access to the latest treatments in HIV through our studies at The Immunology Center. Tashima says that she and other researchers in the ACTG look forward to more promising results coming from the research afforded by the grant renewal, which will allow The Miriam to continue to serve as an ACTG clinical research site for the 2014-2020 time period.


'/>"/>

Contact: Elena Falcone-Relvas
efalconerelvas@lifespan.org
401-793-7484
Lifespan
Source:Eurekalert

Related medicine news :

1. Miriam Hospital study shows social gaming site effective weight loss tool
2. Miriam Hospital study links intimate partner violence and risk of HIV
3. Miriam Hospital researcher awarded $2.9 million NIH grant to study impact of maternal smoking
4. Miriam researcher helps develop global hepatitis C recommendations for injection-drug users
5. Miriam study reveals financial benefits of a plant-based, Mediterranean diet
6. Miriam researchers urge physicians to ask younger men about erectile dysfunction symptoms
7. Smartphone app reads blood oxygen levels to hospital standards, advances to global obstetrics tests
8. Hospital food safety measures reduce risk of contaminated hospital food
9. One in 5 US hospitals dont put hand sanitizer everywhere needed to prevent infections
10. Better nurse staffing and education reduces patient deaths in European hospitals
11. Stand-alone facility for organ retrieval is more efficient, less costly than hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, ... the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the ... April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology: